Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 15 | 2022 | 935 | 3.110 |
Why?
|
| Receptors, Calcitriol | 5 | 2024 | 69 | 2.630 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2024 | 767 | 2.520 |
Why?
|
| Breast Neoplasms | 14 | 2024 | 1502 | 1.520 |
Why?
|
| MicroRNAs | 4 | 2024 | 426 | 1.400 |
Why?
|
| Naphthoquinones | 5 | 2020 | 36 | 1.230 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 628 | 1.150 |
Why?
|
| Prognosis | 8 | 2021 | 739 | 1.060 |
Why?
|
| Vitamin D | 3 | 2022 | 196 | 0.770 |
Why?
|
| Sunbathing | 1 | 2020 | 8 | 0.760 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 117 | 0.750 |
Why?
|
| Promoter Regions, Genetic | 4 | 2020 | 515 | 0.710 |
Why?
|
| Middle Aged | 22 | 2024 | 10129 | 0.650 |
Why?
|
| Humans | 42 | 2024 | 37093 | 0.640 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 17 | 0.640 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 29 | 0.630 |
Why?
|
| Case-Control Studies | 8 | 2024 | 1130 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 807 | 0.610 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 188 | 0.610 |
Why?
|
| Aged | 16 | 2024 | 6741 | 0.610 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 118 | 0.590 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 803 | 0.580 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 448 | 0.560 |
Why?
|
| Carrier Proteins | 2 | 2015 | 305 | 0.540 |
Why?
|
| Apoptosis | 6 | 2020 | 1398 | 0.530 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 421 | 0.520 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.520 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 34 | 0.510 |
Why?
|
| Metabolomics | 1 | 2014 | 81 | 0.480 |
Why?
|
| Age Factors | 1 | 2017 | 1033 | 0.470 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2018 | 29 | 0.470 |
Why?
|
| Male | 16 | 2022 | 20025 | 0.440 |
Why?
|
| Female | 23 | 2024 | 20969 | 0.410 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1198 | 0.410 |
Why?
|
| Plant Extracts | 1 | 2015 | 286 | 0.400 |
Why?
|
| Androgens | 2 | 2011 | 89 | 0.370 |
Why?
|
| BRCA2 Protein | 2 | 2017 | 37 | 0.370 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 16 | 0.360 |
Why?
|
| Receptor, erbB-2 | 3 | 2021 | 133 | 0.360 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 2231 | 0.360 |
Why?
|
| Adult | 13 | 2024 | 11712 | 0.350 |
Why?
|
| RNA, Messenger | 3 | 2021 | 1207 | 0.350 |
Why?
|
| Benzamides | 1 | 2010 | 78 | 0.340 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2008 | 3 | 0.310 |
Why?
|
| Gentamicins | 1 | 2008 | 10 | 0.310 |
Why?
|
| Complement Activation | 1 | 2008 | 13 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 54 | 0.310 |
Why?
|
| Risk | 3 | 2015 | 267 | 0.270 |
Why?
|
| Cell Cycle | 5 | 2018 | 326 | 0.270 |
Why?
|
| Mutation | 2 | 2017 | 1095 | 0.270 |
Why?
|
| Escherichia coli | 1 | 2008 | 453 | 0.250 |
Why?
|
| Genotype | 5 | 2024 | 730 | 0.240 |
Why?
|
| Receptors, Progesterone | 3 | 2018 | 81 | 0.240 |
Why?
|
| Receptors, Estrogen | 3 | 2018 | 156 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 893 | 0.220 |
Why?
|
| Cell Survival | 6 | 2020 | 864 | 0.210 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 626 | 0.210 |
Why?
|
| Blotting, Western | 3 | 2010 | 859 | 0.210 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 92 | 0.200 |
Why?
|
| beta-Crystallin B Chain | 1 | 2021 | 2 | 0.200 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 26 | 0.200 |
Why?
|
| ROC Curve | 1 | 2021 | 138 | 0.190 |
Why?
|
| Haplotypes | 3 | 2020 | 182 | 0.190 |
Why?
|
| Tamoxifen | 1 | 2020 | 65 | 0.180 |
Why?
|
| RNA Interference | 1 | 2021 | 243 | 0.180 |
Why?
|
| Phosphoproteins | 1 | 2021 | 163 | 0.180 |
Why?
|
| Histones | 1 | 2021 | 190 | 0.180 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 146 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 312 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2018 | 325 | 0.170 |
Why?
|
| Interleukin-10 | 1 | 2020 | 75 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 213 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 194 | 0.170 |
Why?
|
| Risk Factors | 4 | 2020 | 3562 | 0.170 |
Why?
|
| Computational Biology | 1 | 2021 | 293 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 513 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 251 | 0.160 |
Why?
|
| Cyclins | 1 | 2018 | 37 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 26 | 0.160 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2018 | 43 | 0.160 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 431 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 39 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 54 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 113 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 48 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2020 | 83 | 0.140 |
Why?
|
| Flow Cytometry | 2 | 2009 | 399 | 0.140 |
Why?
|
| Isoquinolines | 2 | 2007 | 45 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 251 | 0.130 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.130 |
Why?
|
| Social Class | 1 | 2018 | 247 | 0.130 |
Why?
|
| Emetine | 1 | 2015 | 13 | 0.130 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 182 | 0.130 |
Why?
|
| United States | 4 | 2017 | 4223 | 0.130 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.130 |
Why?
|
| Dipeptides | 1 | 2014 | 32 | 0.120 |
Why?
|
| NAD | 1 | 2014 | 50 | 0.120 |
Why?
|
| Methylation | 1 | 2014 | 113 | 0.120 |
Why?
|
| Metabolome | 1 | 2014 | 53 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2015 | 81 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 67 | 0.120 |
Why?
|
| Myoblasts | 1 | 2014 | 27 | 0.120 |
Why?
|
| Osteopontin | 1 | 2014 | 36 | 0.120 |
Why?
|
| Amino Acids | 1 | 2014 | 145 | 0.120 |
Why?
|
| Nicotine | 2 | 2007 | 257 | 0.120 |
Why?
|
| Glutathione | 1 | 2014 | 179 | 0.120 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 12 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2014 | 168 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 69 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 191 | 0.110 |
Why?
|
| Smoking | 1 | 2020 | 940 | 0.110 |
Why?
|
| Plant Roots | 1 | 2015 | 158 | 0.110 |
Why?
|
| Alleles | 3 | 2020 | 321 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 282 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2011 | 9 | 0.100 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.100 |
Why?
|
| Age of Onset | 2 | 2017 | 100 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 623 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2379 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 108 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2009 | 75 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 56 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 8 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 60 | 0.080 |
Why?
|
| Cell Death | 3 | 2021 | 267 | 0.080 |
Why?
|
| Neurotoxins | 2 | 2007 | 57 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 502 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 448 | 0.080 |
Why?
|
| Complement C5b | 1 | 2008 | 1 | 0.080 |
Why?
|
| Complement Pathway, Classical | 1 | 2008 | 2 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2008 | 21 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 66 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 27 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 81 | 0.070 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 67 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 974 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2003 | 3 | 0.060 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 6 | 0.060 |
Why?
|
| Pedigree | 1 | 2003 | 79 | 0.060 |
Why?
|
| Heterozygote | 1 | 2003 | 93 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2003 | 87 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 132 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2003 | 83 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 245 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2021 | 9 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 223 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 52 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 122 | 0.050 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 31 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2003 | 387 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 78 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2020 | 177 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 97 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice | 2 | 2021 | 5913 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 26 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 44 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 33 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 90 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 142 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 73 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 461 | 0.040 |
Why?
|
| District of Columbia | 1 | 2018 | 71 | 0.040 |
Why?
|
| Rabbits | 1 | 2018 | 283 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 1455 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 93 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 275 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 37 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 325 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 753 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 290 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 269 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 311 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 335 | 0.030 |
Why?
|
| Neuroblastoma | 2 | 2007 | 129 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4268 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 602 | 0.030 |
Why?
|
| Sunlight | 1 | 2014 | 47 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2014 | 23 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1369 | 0.030 |
Why?
|
| New York | 1 | 2013 | 71 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 15081 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 111 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 1908 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 202 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 441 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 2026 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 578 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 481 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 674 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 265 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1354 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 465 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 17 | 0.020 |
Why?
|
| Oncogenes | 1 | 2009 | 43 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 618 | 0.020 |
Why?
|
| Exercise | 1 | 2014 | 613 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 306 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 26 | 0.020 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 37 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 601 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.020 |
Why?
|
| Conotoxins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Thiazoles | 1 | 2005 | 74 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 141 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2004 | 455 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1039 | 0.010 |
Why?
|